Showing results (591-600 of 673) with videos related to

Sort By:
Pageof 68
HIV Clinical Trials|June 29, 2005
Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-upRomina Quercia, Elisabeth Garnier, Virginie Ferré, et al.
HIV Clinical Trials|November 25, 2004
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosisG Guaraldi, G Orlando, G Madeddu, et al.
HIV Clinical Trials|February 1, 2005
Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra)Alain Lafeuillade, Gilles Hittinger, Gisèle Philip, et al.
HIV Clinical Trials|October 30, 2003
Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patientsJ Fernández-Rivera, R García, F Lozano, et al.
HIV Clinical Trials|October 30, 2003
Patient acceptance of self-injected enfuvirtide at 8 and 24 weeksCalvin Cohen, James Hellinger, Margaret Johnson, et al.
HIV Clinical Trials|February 6, 2010
Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjectsCarosi, Lazzarin, Stellbrink, et al.
HIV Clinical Trials|February 6, 2010
Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in SpainMoreno, Clotet, Sarría, et al.
HIV Clinical Trials|April 10, 2018
Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant womenCarlos Brites, Isabella Nóbrega, Estela Luz, et al.
HIV Clinical Trials|April 21, 2018
PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infectionKush Dhody, Nader Pourhassan, Kazem Kazempour, et al.
HIV Clinical Trials|July 11, 2017
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTIAnton Pozniak, Jason Flamm, Andrea Antinori, et al.
Pageof 68